ATE360630T1 - Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors - Google Patents

Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors

Info

Publication number
ATE360630T1
ATE360630T1 AT04814952T AT04814952T ATE360630T1 AT E360630 T1 ATE360630 T1 AT E360630T1 AT 04814952 T AT04814952 T AT 04814952T AT 04814952 T AT04814952 T AT 04814952T AT E360630 T1 ATE360630 T1 AT E360630T1
Authority
AT
Austria
Prior art keywords
sup
formula
modulators
cannabinoid receptor
therapeutic agents
Prior art date
Application number
AT04814952T
Other languages
English (en)
Inventor
Guixue Yu
William R Ewing
Amarendra B Mikkilineni
Annapurna Pendri
Philip M Sher
Samuel Gerritz
Bruce A Ellsworth
Gang Wu
Yanting Huang
Chongqing Sun
Natesan Murugesan
Zhengxiang Gu
Ying Wang
Doree Sitkoff
Stephen R Johnson
Ximao Wu
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE360630T1 publication Critical patent/ATE360630T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
AT04814952T 2003-12-19 2004-12-17 Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors ATE360630T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53145103P 2003-12-19 2003-12-19
US11/016,135 US7378418B2 (en) 2003-12-19 2004-12-17 Azabicyclic heterocycles as cannabinoid receptor modulators

Publications (1)

Publication Number Publication Date
ATE360630T1 true ATE360630T1 (de) 2007-05-15

Family

ID=34703659

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04814952T ATE360630T1 (de) 2003-12-19 2004-12-17 Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors

Country Status (19)

Country Link
US (1) US7378418B2 (de)
EP (1) EP1697370B1 (de)
JP (1) JP2007514768A (de)
AT (1) ATE360630T1 (de)
AU (1) AU2004309365A1 (de)
BR (1) BRPI0417771A (de)
CA (1) CA2550435A1 (de)
CY (1) CY1106674T1 (de)
DE (1) DE602004006165T2 (de)
DK (1) DK1697370T3 (de)
ES (1) ES2282927T3 (de)
HR (1) HRP20070241T3 (de)
IL (1) IL176107A0 (de)
IS (1) IS8502A (de)
NO (1) NO20062704L (de)
PL (1) PL1697370T3 (de)
PT (1) PT1697370E (de)
RU (1) RU2006126122A (de)
WO (1) WO2005063761A1 (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210590A1 (en) * 1995-09-27 2010-08-19 Northwestern University Compositions and treatments for seizure-related disorders
EP2264014A1 (de) 2001-08-31 2010-12-22 Université Louis Pasteur Substituierte Pyridazine als Entzündungshemmer und Proteinkinasehemmer
DE602004024814D1 (de) * 2003-11-04 2010-02-04 Merck & Co Inc Substituierte naphthyridinonderivate
WO2006050389A2 (en) 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds, compositions and methods
EP1812007B1 (de) 2004-11-02 2011-09-07 Northwestern University Pyridazinverbindungen und verfahren
MX2007012253A (es) * 2005-04-04 2007-12-07 Univ Pontificia Catolica Chile Uso de ezetimibe para la prevencion y tratamiento de calculos de colesterol en la via biliar.
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
WO2007080720A1 (ja) * 2005-12-07 2007-07-19 Sumitomo Chemical Company, Limited ピリダジン化合物およびその用途
WO2007071023A1 (en) * 2005-12-20 2007-06-28 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
WO2007102999A2 (en) * 2006-02-21 2007-09-13 Ampla Pharmaceuticals Inc. Cb1 antagonists and inverse agonists
WO2007127474A2 (en) * 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
US20090325973A1 (en) 2006-04-28 2009-12-31 Watterson D Martin Formulations containing pyridazine compounds
AR061637A1 (es) * 2006-06-26 2008-09-10 Epix Delaware Inc Composiciones y metodos de tratamiento de trastornos del snc
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
EP2051696A2 (de) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stabile flüssige levetiracetam-zusammensetzungen und verfahren
JP5162598B2 (ja) * 2006-11-30 2013-03-13 ダウ アグロサイエンシィズ エルエルシー ２−置換−５−（１−アルキルチオ）アルキルピリミジンの製造方法
EP1974608A1 (de) * 2007-03-30 2008-10-01 Bayer CropScience AG Arylpyridazine als Fungizide
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
CN105250285B (zh) 2007-04-11 2019-09-06 奥默罗斯公司 预防和治疗成瘾的组合物和方法
EA201000046A1 (ru) * 2007-06-21 2011-02-28 Кара Терапеутикс, Инк. Замещенные имидазогетероциклы
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2008299921B2 (en) 2007-09-13 2012-03-01 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
EP2042491A1 (de) * 2007-09-14 2009-04-01 Bayer CropScience AG Pyridazine als Fungizide
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
CN101590239B (zh) * 2008-05-30 2013-03-27 北京奥萨医药研究中心有限公司 含有利尿剂、他汀和叶酸的药物组合物及其用途
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010018874A1 (en) * 2008-08-12 2010-02-18 Takeda Pharmaceutical Company Limited Amide compound
WO2010045522A2 (en) * 2008-10-16 2010-04-22 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
WO2010045529A2 (en) * 2008-10-16 2010-04-22 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
US20100113604A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
US20100113603A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
US20100113583A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
WO2010151503A2 (en) * 2009-06-25 2010-12-29 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
WO2010151565A2 (en) * 2009-06-26 2010-12-29 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
WO2011008490A2 (en) * 2009-06-29 2011-01-20 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
WO2011009115A2 (en) * 2009-07-17 2011-01-20 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
CN102869775A (zh) 2009-09-30 2013-01-09 哈佛大学校长及研究员协会 通过调节自噬抑制基因产物调节自噬的方法
US20110082407A1 (en) * 2009-10-01 2011-04-07 Aronne Louis J Combination Therapies for the Treatment of Obesity
TW201124078A (en) 2009-12-22 2011-07-16 Du Pont Fungicidal 2-(bicyclic aryloxy) carboxamides
EP2518054A1 (de) * 2009-12-24 2012-10-31 Takeda Pharmaceutical Company Limited Amidverbindung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2012030165A2 (ko) 2010-08-31 2012-03-08 서울대학교산학협력단 P P A R δ 활성물질의 태자재프로그래밍용도
CN103298809B (zh) * 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
WO2012087372A1 (en) 2010-12-22 2012-06-28 E. I. Du Pont De Nemours And Company Fungicidal 2-(bicyclic aryloxy)carboxamides
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
JP5437525B1 (ja) 2012-12-28 2014-03-12 株式会社ナード研究所 チロシン誘導体およびチロシン誘導体の製造方法
BR112015024116A2 (pt) 2013-03-27 2017-10-24 Hoffmann La Roche marcadores genéticos para prever capacidade de resposta à terapia
JP6854752B2 (ja) 2014-07-30 2021-04-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｈｄｌ上昇剤又はｈｄｌ模倣剤を用いた治療に対する応答性を予測するための遺伝マーカー
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
SG10202001787QA (en) 2016-06-02 2020-04-29 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
WO2018237349A1 (en) * 2017-06-23 2018-12-27 University Of Washington Inhibitors of typed 1 methionyl-trna synthetase and methods of using them
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
CA3082356A1 (en) 2017-12-01 2019-06-06 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
RU2765721C1 (ru) 2018-06-15 2022-02-02 Пфайзер Инк. Агонисты glp-1 рецептора и их применение
EP3870292A4 (de) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York Kombination von serotonin-spezifischem wiederaufnahmeinhibitor und serotonin-1a-rezeptor-partialagonist zur verminderung von l-dopa-induzierter dyskinesie
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
IL288024B2 (en) 2019-05-14 2025-12-01 Provention Bio Inc Methods and compositions for preventing type
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング，インコーポレイテッド ガレクチン－３を遮断することにより炎症性疾患を処置する方法
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
EP4525836A4 (de) * 2022-05-18 2026-02-25 Hadasit Medical Res Services&Development Ltd Kombination von endocannabinoid- und mtor-hemmern bei der behandlung von neuroendokrinen neoplasmen
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994898A (en) * 1975-10-16 1976-11-30 E. R. Squibb & Sons, Inc. 1,2,4-Triazolo (4,3-b) pyridazin-3-ones
US4515791A (en) * 1980-06-03 1985-05-07 American Cyanamid Company Substituted phenyl-1,2,4-triazolo[2,3-b]pyridazin-3(2H)ones as anti-asthma agents
JPS61106576A (ja) * 1984-10-31 1986-05-24 Nippon Soda Co Ltd トリアゾロピリダジン−３−オン誘導体及び製造方法
AU6003099A (en) * 1998-10-06 2000-04-26 Takeda Chemical Industries Ltd. Fused pyridazine compounds, process for the preparation of the same and uses thereof
JP2002205992A (ja) * 2000-11-08 2002-07-23 Takeda Chem Ind Ltd 二環式トリアゾロン誘導体およびそれを含有する除草剤
US7351826B2 (en) 2003-02-19 2008-04-01 Neurogen Corporation Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds

Also Published As

Publication number Publication date
DE602004006165T2 (de) 2008-01-17
HK1095139A1 (en) 2007-04-27
WO2005063761A1 (en) 2005-07-14
AU2004309365A1 (en) 2005-07-14
RU2006126122A (ru) 2008-01-27
ES2282927T3 (es) 2007-10-16
US7378418B2 (en) 2008-05-27
NO20062704L (no) 2006-09-05
PL1697370T3 (pl) 2007-09-28
IS8502A (is) 2006-06-08
IL176107A0 (en) 2006-10-05
DK1697370T3 (da) 2007-09-17
JP2007514768A (ja) 2007-06-07
BRPI0417771A (pt) 2007-04-17
HRP20070241T3 (hr) 2007-07-31
CY1106674T1 (el) 2012-05-23
EP1697370B1 (de) 2007-04-25
PT1697370E (pt) 2007-05-31
EP1697370A1 (de) 2006-09-06
DE602004006165D1 (de) 2007-06-06
CA2550435A1 (en) 2005-07-14
US20050143381A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
ATE360630T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
ATE360631T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
NO20062689L (no) Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer
AU2003301020A1 (en) Isoquinolinone derivatives and their use as therapeutic agents
SE9904508D0 (sv) New compounds
NO20076357L (no) Azabicykliske heterocykler som cannabinoid reseptor modulatorer
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
SE0401971D0 (sv) Piperidne derivatives
SE0401345D0 (sv) Therapeutic compounds: Pyridine as scaffold
WO2006044362A3 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
SE0402762D0 (sv) Indazole sulphonamide derivatives
SE0401342D0 (sv) Therapeutic compounds
SE9900961D0 (sv) Novel compounds
DE602004011394D1 (en) Thiazolderivate
SE9903997D0 (sv) New compounds
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0102055D0 (sv) New Compounds
SE0301320D0 (sv) Positive modulators of nicotinic acetylcholine receptors
ATE365735T1 (de) Cycloalkylsulfanyl-substituierte benzo böthiophene als therapeutische mittel
SE9902267D0 (sv) New compounds
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
SE0403118D0 (sv) New compounds 2
ATE554092T1 (de) Azabicyclische heterocyclen als cannabinoid- rezeptormodulatoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1697370

Country of ref document: EP

REN Ceased due to non-payment of the annual fee